Profilo
Jean-Paul Renaud is associated with two companies, NovAliX SAS and Urania Therapeutics SAS.
He was the Chief Scientific Officer at NovAliX SAS, which was founded in 2002.
At Urania Therapeutics SAS, he is the President, Director, and Chief Scientific Officer, and the company was founded in 2015.
Posizioni attive di Jean-Paul Renaud
| Società | Posizione | Inizio |
|---|---|---|
Urania Therapeutics SAS
 Urania Therapeutics SAS BiotechnologyHealth Technology Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France. | Fondatore | 01/10/2015 |
Precedenti posizioni note di Jean-Paul Renaud
| Società | Posizione | Fine |
|---|---|---|
NovAliX SAS
 NovAliX SAS BiotechnologyHealth Technology NovAliX SAS operates as a drug discovery-focused contract research organization. It offers drug discovery services in the fields of chemistry, collaborative models, biophysics and biology. The company was founded by Stephan Jenn and Jean-Paul Renaud in 2002 and is headquartered in Illkirch, France. | Fondatore | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
NovAliX SAS
NovAliX SAS BiotechnologyHealth Technology NovAliX SAS operates as a drug discovery-focused contract research organization. It offers drug discovery services in the fields of chemistry, collaborative models, biophysics and biology. The company was founded by Stephan Jenn and Jean-Paul Renaud in 2002 and is headquartered in Illkirch, France. | Health Technology |
Urania Therapeutics SAS
Urania Therapeutics SAS BiotechnologyHealth Technology Urania Therapeutics SAS develops therapeutic solutions for the treatment of genetic diseases caused by pathogenic nonsense mutations. The company was founded by Jean-Paul Renaud, Marat Yusupova, and Gulnara Yusupova in October 2015 and is headquartered in Illkirc, France. | Health Technology |
- Borsa valori
- Insiders
- Jean-Paul Renaud
